Showing 1–9 of 9 results
-
Amendments and Corrections | | Open
Erratum: Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
- Angus G Dalgleish
- , Justin Stebbing
- , Douglas J A Adamson
- , Seema Safia Arif
- , Paolo Bidoli
- , David Chang
- , Sue Cheeseman
- , Robert Diaz-Beveridge
- , Carlos Fernandez-Martos
- , Rob Glynne-Jones
- , Cristina Granetto
- , Bartomeu Massuti
- , Karen McAdam
- , Raymond McDermott
- , Andrés J Muñoz Martín
- , Demetris Papamichael
- , Roberto Pazo-Cid
- , Jose M Vieitez
- , Alberto Zaniboni
- , Kevin J Carroll
- , Shama Wagle
- , Andrew Gaya
- & Satvinder S Mudan
-
Research | | Open
-
| Open
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer
- Angus G Dalgleish
- , Justin Stebbing
- , Douglas JA Adamson
- , Seema Safia Arif
- , Paolo Bidoli
- , David Chang
- , Sue Cheeseman
- , Robert Diaz-Beveridge
- , Carlos Fernandez-Martos
- , Rob Glynne-Jones
- , Cristina Granetto
- , Bartomeu Massuti
- , Karen McAdam
- , Raymond McDermott
- , Andrés J Muñoz Martín
- , Demetris Papamichael
- , Roberto Pazo-Cid
- , Jose M Vieitez
- , Alberto Zaniboni
- , Kevin J Carroll
- , Shama Wagle
- , Andrew Gaya
- & Satvinder S Mudan
-
Research |
-
-
Research |
-
Research |
-
Research |
-
Research | | Open